Colonic neoplasm
MONDO:0005401A benign or malignant neoplasm that affects the colon. Representative examples of benign neoplasms include lipoma and leiomyoma. Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma. Colonic adenomas always exhibit epithelial dysplasia and are considered premalignant neoplasms.
Also known as: colon neoplasm, colon neoplasm (disease), colon tumor, colon tumour, colonic neoplasm, colonic tumor, colonic tumour, neoplasm of colon
2070 clinical trials for this condition and its sub-types, 461 tagged with Colonic neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Colonic neoplasm
-
Malignant colon neoplasm 62 trials · 439 incl. sub-types
9 sub-types
- Colon carcinoma 279 trials · 379 incl. sub-types Sub-types →
- Cecum cancer 0 trials · 53 incl. sub-types Sub-types →
- Metastasis from malignant tumor of colon 27 trials
- Sigmoid colon cancer 9 trials · 14 incl. sub-types Sub-types →
- Ascending colon cancer 9 trials · 10 incl. sub-types Sub-types →
- Transverse colon cancer 2 trials
- Descending colon cancer 0 trials · 1 incl. sub-types Sub-types →
- Colon lymphoma 0 trials Sub-types →
- Colon sarcoma 0 trials Sub-types →
-
Epithelial tumor of colon 0 trials · 409 incl. sub-types
4 sub-types
- Colon carcinoma 279 trials · 379 incl. sub-types Sub-types →
- Epithelial tumor of the appendix 0 trials · 42 incl. sub-types Sub-types →
- Colon adenoma 17 trials · 32 incl. sub-types Sub-types →
- Neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor 0 trials · 5 incl. sub-types Sub-types →
-
Cecal neoplasm 0 trials · 59 incl. sub-types
5 sub-types
- Appendiceal neoplasm 30 trials · 56 incl. sub-types Sub-types →
- Cecum cancer 0 trials · 53 incl. sub-types Sub-types →
- Cecum neuroendocrine tumor G1 3 trials Sub-types →
- Benign neoplasm of cecum 0 trials Sub-types →
- Cecum villous adenoma 0 trials Sub-types →
-
Sigmoid neoplasm 7 trials · 17 incl. sub-types
2 sub-types
- Sigmoid colon cancer 9 trials · 14 incl. sub-types Sub-types →
- Rectosigmoid junction neoplasm 0 trials · 5 incl. sub-types Sub-types →
-
Colon neuroendocrine neoplasm 0 trials · 5 incl. sub-types
3 sub-types
- Neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor 0 trials · 5 incl. sub-types Sub-types →
- Appendix neuroendocrine neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Colon small cell neuroendocrine carcinoma 0 trials
-
Benign colon neoplasm 2 trials
5 sub-types
- Benign neoplasm of cecum 0 trials Sub-types →
- Cavernous hemangioma of colon 0 trials
- Colon leiomyoma 0 trials Sub-types →
- Colonic lymphangioma 0 trials
- Lipoma of colon 0 trials
-
Colon inflammatory polyp 0 trials
-
Colon juvenile polyp 0 trials
Most studied deeper sub-types
-
Can a new drug combo revive Immunotherapy's power against resistant tumors?
Disease control Stopped earlyThis trial is testing whether an experimental drug called NC410, when combined with the immunotherapy drug pembrolizumab, can safely and effectively treat people with advanced solid tumors that have not responded to standard immunotherapy or that are unlikely to respond. The stud…
Phase 1/2 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Pfizer's new cancer pill tested in advanced tumors – study halted early
Disease control Stopped earlyThis early-stage study tested a new cancer pill (PF-07985045) alone or with other drugs in people with advanced solid tumors that have a KRAS gene mutation. The trial included patients with lung, colon, or pancreatic cancer. The study aimed to check safety and find the right dose…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental cell therapy targets tough cancers, but trial ends early
Disease control Stopped earlyThis early-phase trial tested a new approach: taking a patient's own white blood cells, genetically modifying them in the lab to recognize a specific cancer mutation (KRAS G12D), and infusing them back to attack tumors. The study enrolled only 5 adults with advanced gastrointesti…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental cancer drug trial halted early
Disease control Stopped earlyThis study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head…
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental cancer drug AUR106 tested in humans for first time
Disease control Stopped earlyThis early-stage trial tested an experimental drug called AUR106 in 21 adults with advanced solid tumors (lung, stomach, bladder, kidney, colon, or esophageal cancer) that had come back or spread. The main goals were to check safety, find the right dose, and see how the drug move…
Phase 1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill for Hard-to-Treat cancers shows early promise in small study
Disease control Stopped earlyThis early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Accent Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for Hard-to-Treat colon cancer? study tests targeted drug combo
Disease control Stopped earlyThis study tested whether adding the experimental drug ompenaclid to standard chemotherapy could shrink tumors in people with advanced colorectal cancer that has a RAS gene mutation. About 76 participants were randomly assigned to receive either ompenaclid or a placebo, along wit…
Phase 2 • Sponsor: Inspirna, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental cancer drug trial halted early – what we know
Disease control Stopped earlyThis early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors that have certain gene mutations (KRAS-MAPK pathway). The main goals were to check safety and how the drug moves through the body. The trial w…
Phase 1 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Turmeric compound tested against tough colon cancer
Disease control Stopped earlyThis early-stage study tested whether adding curcumin (a compound in turmeric) to standard chemotherapy could help patients with metastatic colon cancer that no longer responds to 5FU. The goal was to check safety and see if the combination shrinks tumors. Only 15 people were enr…
Early phase 1 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cancer drug tested in people with advanced tumors
Disease control Stopped earlyThis early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was…
Phase 1 • Sponsor: Pheon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktails tested for tough colorectal cancer
Disease control Stopped earlyThis early-phase study tested several drug combinations in 122 adults with advanced or metastatic BRAF V600 colorectal cancer. The goal was to find safe doses and understand side effects. The trial was terminated, so final results are not available.
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental cancer drug TAK-186 tested in patients with advanced tumors
Disease control Stopped earlyThis study tested a new drug called TAK-186 in 95 adults with advanced or metastatic cancers of the head and neck, lung, or colon that could not be removed by surgery. The main goal was to check for side effects and find the best dose. The study was stopped early, so results are …
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Targeted drug shows promise for rare genetic cancers
Disease control Stopped earlyThis study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…
Phase 2 • Sponsor: Tempus AI • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo for colorectal cancer shows promise but trial halted early
Disease control Stopped earlyThis phase 2 trial tested a new drug combination (NUFIRI-bev) against the standard treatment (FOLFIRI-bev) in 171 people with metastatic colorectal cancer that had already been treated. The goal was to see if the new combo could delay cancer growth better than the standard. Howev…
Phase 2 • Sponsor: NuCana plc • Aim: Disease control
Last updated Jun 26, 2026 15:54 UTC
-
Study probes immune changes after heat ablation of lung tumors
Knowledge-focused Stopped earlyThis study looked at how radiofrequency ablation (RFA), a procedure that uses heat to destroy tumors, affects the immune system in people with lung metastases from colorectal cancer. Researchers measured immune cells in tumor samples and blood before and after RFA in 20 participa…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC